Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IBIO
IBIO, INC.
NASDAQ
$1.36
▼ DOWN 2.86% (-0.04)

KEY STATISTICS

Market Cap$21.47 M
52w High$3.82
52w Low$0.77
Dividend Yield—
Frequency—
P/E-4.39
Volume512.32K
Shares Out.15.79M

COMPANY

LEADERSHIP

Martin Brenner
CHIEF EXECUTIVE
Martin Brenner

COMPENSATION 2026

Salary$539,366
Stock Awards$0
Incentive Plan Pay$161,411
All Other Comp.$9,858
Total$1,509,907

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 19, 2008
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
20

PRICE TARGET

Target High$5.00
Target Low$5.00
Target Median$5.00
Target Consensus$5.00

UPCOMING EARNINGS

DateNov 17, 2026
DayTuesday
Rev. Est.$33.33K
NOV
17
TUE

SPLIT RECORD

DATETYPERATIO
2023-11-29Reverse1:20
2022-10-10Reverse1:25
2018-06-11Reverse1:10

PRICE

$1.36 ▼ DOWN 2.86% (−$0.04)
OVERLAYS
$1.35$1.38$1.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.36

About iBio, Inc.

https://www.ibioinc.com ↗

iBio, Inc. is a Texas-based biotech firm offering contract development, manufacturing, and development of therapeutics and vaccines, including candidates for scleroderma, pulmonary fibrosis, COVID-19, and other diseases.

INDUSTRY

Biotechnology

A PRODUCT IBIO, INC. IS KNOWN FOR

IBIO-600
IBIO-600

IBIO-600 is a long-acting monoclonal antibody targeting myostatin to preserve muscle mass in obesity, with Phase 1a trials planned for early 2026.

COMPETITORS

COMPETITOR
ALT COMPARE
AMGN COMPARE
LLY COMPARE
NVO COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ4-2021Q1-2022Q2-2022Q3-2022
Ibio Inc$1K $84K ▲$0 ▼$1.8M ▲
Ibio Cdmo$491K $127K ▼$168K ▲$143K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
13
LISTED HERE
2
RANKED BY POSITION SIZE
VTI
0.00% · 1.5M
IWC
0.01% · 105.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
72
TOP 12 OF 72 · RANKED BY POSITION SIZE
Affinity Asset Advisors, LLC
3.1M sh · $5.9M
Ecor1 Capital, LLC
2.2M sh · $4.3M
Logos Global Management LP
2.0M sh · $3.86M
Frazier Life Sciences Management, L.P.
2.0M sh · $3.71M
Millennium Management LLC
1.5M sh · $2.94M
Balyasny Asset Management L.P.
1.1M sh · $2.12M
Lynx1 Capital Management LP
1.1M sh · $874.07K
Ikarian Capital, LLC
957.1K sh · $1.82M
Citadel Advisors LLC
956.4K sh · $1.82M
Sio Capital Management, LLC
904.3K sh · $1.72M
Vanguard Group Inc
883.1K sh · $1.7M
Marshall Wace, Llp
620.6K sh · $1.18M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER
Carr Molly
— · —
2026-07-31
★
OFFICER: CHIEF MEDICAL OFFICER
Carr Molly
Purchase · 430.0K shares
2026-07-31
★
DIRECTOR
Stoner Elizabeth
Purchase · 60.0K shares
2026-05-18
★
DIRECTOR:
Stoner Elizabeth
— · —
2026-05-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY

SECTORS PEERS

PEERPRICE
ANTX$5.58COMPARE
RLYB$16.81COMPARE
BOLD$2.83COMPARE
PLUR$1.53COMPARE
INTS$4.25COMPARE
XCUR$1.29COMPARE
CVKD$1.54COMPARE